Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.

Future Oncology
Liana Nikolaenko, Auayporn Nademanee

Abstract

Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, is US FDA approved for treatment of classic Hodgkin lymphoma (cHL) after progression or relapse of at least two prior lines of chemotherapy or autologous stem cell transplantation, as consolidation therapy after autologous stem cell transplantation for high-risk patients and as a front-line therapy for previously untreated, advanced-stage cHL in combination with chemotherapy. BV is a well-tolerated treatment in previously heavily pretreated relapsed/refractory cHL and in treatment-naive patients. BV use, in combination with other antineoplastic agents for cHL, is under investigation in multiple prospective clinical trials.

References

Jan 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroF Crippa
Feb 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P J BiermanJ O Armitage
Mar 1, 1997·Molecular and Cellular Biology·C S DuckettC B Thompson
Aug 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Helena HarlinMaria-Luisa Alegre
Mar 1, 1997·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·A MenaU M Kabadi
Mar 26, 2009·Journal of the National Cancer Institute·Nadia HowladerBrenda K Edwards
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Apr 5, 2012·Clinical Neurology and Neurosurgery·Pankaj JalanJanak Koirala
Jun 12, 2012·MAbs·Niels W C J van de Donk, Eugen Dhimolea
Mar 20, 2014·Journal of Hematology & Oncology·Nancy L BartlettAndres Forero-Torres
Aug 20, 2014·British Journal of Haematology·Graham W SlackRandy D Gascoyne
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Apr 23, 2015·The New England Journal of Medicine·John RadfordSally Barrington
Jul 28, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert ChenStephen J Forman
Apr 21, 2016·Expert Opinion on Biological Therapy·R DadaRawan Al Saadi
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ChenUNKNOWN KEYNOTE-087
Dec 12, 2017·The New England Journal of Medicine·Joseph M ConnorsUNKNOWN ECHELON-1 Study Group
Jun 3, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Auayporn NademaneeJohn Sweetenham
Sep 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M EvensPaul A Hamlin
Jan 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Radhakrishnan RamchandrenDavid J Straus
Jan 19, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Garcia-SanzC Martinez
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Garcia-SanzC Martinez

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
ICE

Clinical Trials Mentioned

NCT01716806
NCT03013933
NCT02744612
NCT03057795
NCT02758717
NCT02572167

Software Mentioned

ECHELON
ADCETRIS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.